Information Provided By:
Fly News Breaks for October 15, 2015
OMCL
Oct 15, 2015 | 07:13 EDT
Oppenheimer blames Omnicell's Q2 miss largely on implementation delays. The firm says that the company has experienced such delays in the past, and it does not expect the latest delays to alter the company's ability to compete. The firm thinks the company has a number of positive catalysts, including its strengthening market position, its key competitor's weakness, and a slow ramp-up of medication adherence in the U.S. Oppenheimer keeps a $42 price target and Outperform rating on the shares.
News For OMCL From the Last 2 Days
There are no results for your query OMCL